BMB-101
Small molecule
Evidence outlook
Epilepsy: topline reported 2026-01-06
The sponsor reported topline results on 2026-01-06 (Phase 2 BREAKTHROUGH of BMB-101 reported positive topline results in absence seizures and DEE). The announcement is listed under Regulatory events.
Also in development:Developmental and Epileptic Encephalopathies · Phase 2Absence Seizures · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06401538 NCT06401538 · Absence Epilepsy, Jeavons Syndrome, Dravet Syndrome, Lennox Gastaut Syndrome Registry: NCT06401538 | 2 | Change from baseline in seizure frequency in DEE subjects (10 weeks); Change from baseline in the number of generalized spike-wave discharges (GSWD) on the 24 hr EEG in Absence subjects. (6 weeks) 2025-09-15 | In progress: primary completion was expected 15 Sept 2025; results not posted | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (2)
What this study did
What this study did
Phase 1 (1)
What this study did
Competitive landscape
This drug's own stage for Absence Seizures: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| BMB-101: this drug | Phase 2 | Small molecule | Serotonin 5-HT2C receptor (biased agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Divalproex Sodium (Depakote ER) | Approved | Small molecule | GABAergic neurotransmission | not yet graded | No reviewed efficacy summary in this indication | |
| Divalproex Sodium (Depakote) | Approved | Small molecule | GABAergic neurotransmission | not yet graded | No reviewed efficacy summary in this indication | |
| Valproate | ApprovedUS marketing discontinued | Small molecule | GABAergic neurotransmission | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow BMB-101 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
November 2026 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent